Oculis (NASDAQ:OCS) Shares Gap Down Following Analyst Downgrade

Oculis Holding AG (NASDAQ:OCS) shares gapped down prior to trading on Monday after Guggenheim lowered their price target on the stock from $75.00 to $45.00. The stock had previously closed at $22.70, but opened at $15.78. Guggenheim currently has a buy rating on the stock. Oculis shares last traded at $14.8860, with a volume of 1,917,583 shares traded.

Other equities research analysts have also issued reports about the company. HC Wainwright reduced their price objective on Oculis from $47.00 to $26.00 and set a “buy” rating for the company in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. JPMorgan Chase & Co. boosted their price target on Oculis from $38.00 to $42.00 and gave the company an “overweight” rating in a report on Monday, May 18th. Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Stifel Nicolaus raised their price objective on Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Hedge Funds Weigh In On Oculis

A number of hedge funds have recently made changes to their positions in the business. Gildi lifeyrissjodur bought a new position in shares of Oculis during the 4th quarter valued at about $50,250,000. Aberdeen Group plc increased its holdings in shares of Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after purchasing an additional 493,827 shares during the last quarter. SR One Capital Management LP lifted its position in shares of Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after buying an additional 318,522 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Oculis in the fourth quarter worth about $9,862,000. Finally, Alyeska Investment Group L.P. boosted its stake in Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after buying an additional 200,000 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Price Performance

The firm has a market cap of $846.04 million, a PE ratio of -6.84 and a beta of 0.23. The firm has a fifty day simple moving average of $27.68 and a two-hundred day simple moving average of $25.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. Equities analysts predict that Oculis Holding AG will post -2.21 EPS for the current fiscal year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.